litlas
Log inCreate account

Gary M. Clark

Active 1979–2022

96
Papers
47,946
Citations
86
h-index
96
i10-index

Citations

Citations per year for Gary M. Clark1974: 1 citations1979: 1 citations1981: 1 citations1983: 9 citations1984: 10 citations1985: 11 citations1986: 19 citations1987: 39 citations1988: 64 citations1989: 81 citations1990: 103 citations1991: 113 citations1992: 149 citations1993: 137 citations1994: 190 citations1995: 155 citations1996: 128 citations1997: 158 citations1998: 208 citations1999: 215 citations2000: 269 citations2001: 310 citations2002: 291 citations2003: 308 citations2004: 388 citations2005: 455 citations2006: 483 citations2007: 506 citations2008: 513 citations2009: 503 citations2010: 513 citations2011: 427 citations2012: 424 citations2013: 391 citations2014: 338 citations2015: 307 citations2016: 238 citations2017: 254 citations2018: 202 citations2019: 690 citations2020: 688 citations2021: 537 citations2022: 394 citations2023: 277 citations2024: 412 citations2025: 155 citations2026: 7 citations1975–1978: no citations, so these years are not shown1980: no citations, so this year is not shown1982: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,973 citing papers, 32.4% of this breakdownUnited Kingdom: 1,124 citing papers, 7.3% of this breakdownChina: 989 citing papers, 6.4% of this breakdownGermany: 765 citing papers, 5% of this breakdownItaly: 758 citing papers, 4.9% of this breakdownCanada: 676 citing papers, 4.4% of this breakdownFrance: 566 citing papers, 3.7% of this breakdownJapan: 535 citing papers, 3.5% of this breakdownNetherlands: 420 citing papers, 2.7% of this breakdownSpain: 417 citing papers, 2.7% of this breakdownAustralia: 364 citing papers, 2.4% of this breakdownSwitzerland: 343 citing papers, 2.2% of this breakdown
0%32.4%Other 22.4%

Institutions

Fields

  • Medicine58.5%
  • Biochemistry, Genetics and Molecular Biology33.6%
  • Computer Science1.8%
  • Immunology and Microbiology1.7%
  • Chemistry0.7%
  • Mathematics0.6%
  • Other3.1%

Topics

  • HER2/EGFR in Cancer Research9.2%
  • Breast Cancer Treatment Studies6.1%
  • Lung Cancer Treatments and Mutations4%
  • Monoclonal and Polyclonal Antibodies Research3.8%
  • Estrogen and related hormone effects2.9%
  • Cancer Genomics and Diagnostics2.5%
  • Other71.5%

Coauthors

All papers

Open in search
  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene

    Authors: Dennis J. Slamon, Gary M. Clark, Steven Wong, Wendy J. Levin, Axel Ullrich, William McGuire - Science 1987 cited by 11,788

  2. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Authors: Malcolm J. Moore, David Goldstein, John Hamm, Arié Figer, J. Randolph Hecht, Steven Gallinger, H. Au, P. Murawa, David Walde, Robert A. Wolff, Daniel de Castro, Robert Lim, Keyue Ding, Gary M. Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy R. Parulekar - Journal of Clinical Oncology 2007 cited by 3,859

  3. REporting recommendations for tumour MARKer prognostic studies (REMARK)

    Authors: Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei, Sheila E. Taube, Massimo Gion, Gary M. Clark - British Journal of Cancer 2005 cited by 1,387

  4. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 cited by 5,451

  5. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

    Authors: Grazia Arpino, V J Bardou, Gary M. Clark, Richard Elledge - Breast Cancer Research 2004 cited by 869

  6. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

    Authors: Jennet Harvey, Gary M. Clark, C. Kent Osborne, D. Craig Allred - Journal of Clinical Oncology 1999 cited by 2,063

  7. Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema: A Randomized Controlled Trial

    Authors: Vincent S. Paramanandam, Elizabeth Dylke, Gary M. Clark, Anuradha A. Daptardar, Ajeeta M. Kulkarni, Nita S. Nair, Rajendra A. Badwe, Sharon L. Kilbreath - Journal of Clinical Oncology 2022 cited by 89

  8. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

    Authors: Valérie‐Jeanne Bardou, Grazia Arpino, Richard Elledge, C. Kent Osborne, Gary M. Clark - Journal of Clinical Oncology 2003 cited by 757

  9. A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment

    Authors: Sheila E. Taube, Gary M. Clark, Janet Dancey, Lisa M. McShane, Caroline C. Sigman, Steven Gutman - JNCI Journal of the National Cancer Institute 2009 cited by 127

  10. Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

    Authors: C. Kent Osborne, V J Bardou, Torsten Hopp, Gary C. Chamness, Susan G. Hilsenbeck, Suzanne A.W. Fuqua, Jiemin Wong, D. Craig Allred, Gary M. Clark, R. Schiff - JNCI Journal of the National Cancer Institute 2003 cited by 782

  11. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

    Authors: Gary M. Clark - Molecular Oncology 2007 cited by 142

  12. Reporting Recommendations for Tumor Marker Prognostic Studies

    Authors: Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei, Sheila E. Taube, Massimo Gion, Gary M. Clark - Journal of Clinical Oncology 2005 cited by 775

  13. Effects of Smoking on the Pharmacokinetics of Erlotinib

    Authors: Marta Hamilton, Julie Wolf, Jason Rusk, Shannon E. Beard, Gary M. Clark, Karsten Witt, Pablo J. Cagnoni - Clinical Cancer Research 2006 cited by 311

  14. Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

    Authors: D. Craig Allred, Gary M. Clark, Richard Elledge, Suzanne A.W. Fuqua, Richard W. Brown, Gary C. Chamness, C. Kent Osborne, William McGuire - JNCI Journal of the National Cancer Institute 1993 cited by 783

  15. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

    Authors: Gary M. Clark, C. Kent Osborne, William McGuire - Journal of Clinical Oncology 1984 cited by 395

  16. Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer

    Authors: Ismail Jatoi, Susan G. Hilsenbeck, Gary M. Clark, C. Kent Osborne - Journal of Clinical Oncology 1999 cited by 301

  17. Redefining adequate margins in oral squamous cell carcinoma: outcomes from close and positive margins

    Authors: Prateek Jain, Rajeev Sharan, Kapila Manikantan, Gary M. Clark, Sanjoy Chatterjee, Indranil Mallick, Paromita Roy, Pattatheyil Arun - European Archives of Oto-Rhino-Laryngology 2020 cited by 23

  18. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    Authors: S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry, Kirby I. Bland, Patrick I. Borgen, Gary M. Clark, Stephen B. Edge, Daniel F. Hayes, Lorie L. Hughes, R. V. P. Hutter, Monica Morrow, David L. Page, Abram Recht, Richard L. Theriault, Ann D. Thor, Donald L. Weaver, H. Samuel Wieand, Frederick L. Greene - Journal of Clinical Oncology 2002 cited by 1,183

  19. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

    Authors: Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark S. Huberman, Daniel D. Karp, James R. Rigas, Gary M. Clark, P. Santabárbara, Philip Bonomi - Journal of Clinical Oncology 2004 cited by 1,086

  20. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas

    Authors: Sami Diab, Gary M. Clark, C. Kent Osborne, Arlene L. Libby, D. Craig Allred, Richard Elledge - Journal of Clinical Oncology 1999 cited by 303

  21. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual

    Authors: S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry, Kirby I. Bland, Patrick I. Borgen, Gary M. Clark, Stephen B. Edge, Daniel F. Hayes, Lorie L. Hughes, R. V. P. Hutter, Monica Morrow, David L. Page, Abram Recht, Richard L. Theriault, Ann D. Thor, Donald L. Weaver, H. Samuel Wieand, Frederick L. Greene - Surgical Clinics of North America 2003 cited by 294

  22. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.

    Authors: C. Kent Osborne, David H. Boldt, Gary M. Clark, Jeffrey M. Trent - 1983 cited by 278

  23. HER-2/neu oncogene protein and prognosis in breast cancer.

    Authors: Amol Tandon, Gary M. Clark, Gary C. Chamness, Axel Ullrich, W L McGuire - Journal of Clinical Oncology 1989 cited by 583

  24. Heat Shock Protein hsp70 in Patients With Axillary Lymph Node-Negative Breast Cancer: Prognostic Implications

    Authors: Daniel R. Ciocca, Gary M. Clark, Amol Tandon, Suzanne A.W. Fuqua, William J. Welch, William McGuire - JNCI Journal of the National Cancer Institute 1993 cited by 362